DRIO
DarioHealth Corp. [DRIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DRIO Stock Summary
Top 10 Correlated ETFs
DRIO
Top 10 Correlated Stocks
DRIO
In the News
DRIO Financial details
Company Rating
Neutral
Market Cap
36.21M
Income
726.06K
Revenue
20.35M
Book val./share
2.14
Cash/share
1.36
Dividend
-
Dividend %
-
Employees
276
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
510.82
Forward P/E
-
PEG
-50.89
P/S
2.25
P/B
0.83
P/C
0.89
P/FCF
-1.68
Quick Ratio
6.21
Current Ratio
6.93
Debt / Equity
0.49
LT Debt / Equity
0.42
-
-
EPS (TTM)
0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-26.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.45%
Revenue last 5Y
21.91%
Revenue Q/Q
2.79%
EPS Q/Q
-174.58%
-
-
-
-
SMA20
-17.83%
SMA50
-35.5%
SMA100
21.7%
Inst Own
21.79%
Inst Trans
0.66%
ROA
-
ROE
-
ROC
-0.52%
Gross Margin
36%
Oper. Margin
-217%
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.68-4.58
52W High
-
52W Low
-
RSI
38.42
Rel Volume
0.44
Avg Volume
137.49K
Volume
59.91K
Perf Week
-15.38%
Perf Month
-27.98%
Perf Quarter
-41.26%
Perf Half Y
-54.51%
-
-
-
-
Beta
1.656
-
-
Volatility
0.1%, 0.16%
Prev Close
3.42%
Price
1.21
Change
5.22%
DRIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.34 | 1.27 | 1.24 | 1.17 | 0.72 | |
| Net income per share | -7.84 | -4.86 | -4.63 | -2.63 | -1.93 | |
| Operating cash flow per share | -6.94 | -2.97 | -3.04 | -2.02 | -1.07 | |
| Free cash flow per share | -6.98 | -2.99 | -3.05 | -2.05 | -1.09 | |
| Cash per share | 9 | 4.79 | 2.16 | 2.09 | 1.31 | |
| Book value per share | 8.34 | 4.72 | 5.16 | 3.38 | 2.05 | |
| Tangible book value per share | 8.34 | 4.72 | 1.9 | 1.2 | 0.39 | |
| Share holders equity per share | 8.34 | 4.72 | 5.16 | 3.38 | 2.05 | |
| Interest debt per share | 0.35 | 0.1 | 0.02 | 1.27 | 1.01 | |
| Market cap | 14.87M | 85.22M | 215.19M | 101.16M | 48.8M | |
| Enterprise value | -4.76M | 57.16M | 179.67M | 79.85M | 41.25M | |
| P/E ratio | -0.84 | -2.94 | -2.8 | -1.63 | -0.89 | |
| Price to sales ratio | 1.97 | 11.25 | 10.49 | 3.66 | 2.4 | |
| POCF ratio | -0.95 | -4.8 | -4.27 | -2.11 | -1.61 | |
| PFCF ratio | -0.94 | -4.77 | -4.25 | -2.09 | -1.58 | |
| P/B Ratio | 0.79 | 3.03 | 2.52 | 1.26 | 0.84 | |
| PTB ratio | 0.79 | 3.03 | 2.52 | 1.26 | 0.84 | |
| EV to sales | -0.63 | 7.54 | 8.76 | 2.89 | 2.03 | |
| Enterprise value over EBITDA | 0.27 | -1.9 | -2.46 | -1.52 | -0.81 | |
| EV to operating cash flow | 0.3 | -3.22 | -3.56 | -1.67 | -1.36 | |
| EV to free cash flow | 0.3 | -3.2 | -3.55 | -1.65 | -1.33 | |
| Earnings yield | -1.2 | -0.34 | -0.36 | -0.61 | -1.12 | |
| Free cash flow yield | -1.06 | -0.21 | -0.24 | -0.48 | -0.63 | |
| Debt to equity | 0.04 | 0.02 | 0 | 0.35 | 0.49 | |
| Debt to assets | 0.03 | 0.02 | 0 | 0.24 | 0.3 | |
| Net debt to EBITDA | 1.12 | 0.93 | 0.49 | 0.41 | 0.15 | |
| Current ratio | 4.39 | 4.85 | 3.17 | 3.39 | 3.77 | |
| Interest coverage | -655.74 | -610.27 | -910.64 | -30.28 | 0 | |
| Income quality | 0.89 | 0.6 | 0.66 | 0.77 | 0.55 | |
| Dividend Yield | 0 | 0 | 0 | 0.24 | 0 | |
| Payout ratio | 0 | 0 | 0 | -0.38 | 0 | |
| Sales general and administrative to revenue | 0.73 | 1.68 | 1.15 | 0.6 | 0.89 | |
| Research and developement to revenue | 0.49 | 0.59 | 0.84 | 0.71 | 0.99 | |
| Intangibles to total assets | 0 | 0 | 0.54 | 0.43 | 0.49 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to revenue | -0.01 | -0.02 | -0.01 | -0.02 | -0.03 | |
| Capex to depreciation | -0.54 | -0.62 | -0.08 | -0.12 | -0.11 | |
| Stock based compensation to revenue | 0.3 | 1.47 | 1.22 | 0.61 | 0.97 | |
| Graham number | 38.35 | 22.72 | 23.17 | 14.16 | 9.44 | |
| ROIC | -0.87 | -1.01 | -0.89 | -0.52 | -0.64 | |
| Return on tangible assets | -0.72 | -0.82 | -1.64 | -0.92 | -1.11 | |
| Graham Net | 7.04 | 3.98 | 1.51 | 0.82 | 0.14 | |
| Working capital | 17.72M | 27.09M | 31.23M | 46.17M | 34.6M | |
| Tangible asset value | 18.89M | 28.15M | 31.45M | 28.44M | 11.1M | |
| Net current asset value | 17.26M | 26.87M | 30.38M | 26.33M | 8.85M | |
| Invested capital | 0.04 | 0.02 | 0 | 0.35 | 0.49 | |
| Average receivables | 473K | 1.21M | 1.75M | 4.46M | 5.27M | |
| Average payables | 2.12M | 2.07M | 3.79M | 3.72M | 1.73M | |
| Average inventory | 1.4M | 1.85M | 4.26M | 7.09M | 6.51M | |
| Days sales outstanding | 34.38 | 82.1 | 31.78 | 94.21 | 61.07 | |
| Days payables outstanding | 121.81 | 178.79 | 112.68 | 47.08 | 28.73 | |
| Days of inventory on hand | 104.01 | 165.31 | 137.35 | 161.32 | 128.59 | |
| Receivables turnover | 10.62 | 4.45 | 11.49 | 3.87 | 5.98 | |
| Payables turnover | 3 | 2.04 | 3.24 | 7.75 | 12.7 | |
| Inventory turnover | 3.51 | 2.21 | 2.66 | 2.26 | 2.84 | |
| ROE | -0.94 | -1.03 | -0.9 | -0.78 | -0.94 | |
| Capex per share | -0.04 | -0.02 | -0.02 | -0.02 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.26 | 0.26 | 0.22 | 0.12 | 0.13 | |
| Net income per share | -0.49 | 0.45 | -0.59 | 0.59 | -0.44 | |
| Operating cash flow per share | -0.31 | -0.17 | -0.34 | -0.3 | -0.27 | |
| Free cash flow per share | -0.31 | -0.18 | -0.35 | -0.31 | -0.27 | |
| Cash per share | 1.92 | 1.56 | 1.87 | 1.52 | 1.36 | |
| Book value per share | 3.11 | 2.61 | 2.78 | 2.36 | 2.14 | |
| Tangible book value per share | 1.11 | 0.78 | 1.03 | 0.69 | 0.41 | |
| Share holders equity per share | 3.11 | 2.61 | 2.78 | 2.36 | 2.14 | |
| Interest debt per share | 1.13 | 1 | 1.07 | 1.04 | 1.07 | |
| Market cap | 110.1M | 113.59M | 113.03M | 94.52M | 46.77M | |
| Enterprise value | 88.79M | 101.17M | 90.55M | 80.56M | 39.22M | |
| P/E ratio | -2.18 | 2.29 | -1.7 | 1.4 | -0.97 | |
| Price to sales ratio | 16.17 | 16.08 | 18.37 | 26.87 | 12.93 | |
| POCF ratio | -13.86 | -23.88 | -11.73 | -10.93 | -6.37 | |
| PFCF ratio | -13.76 | -23.51 | -11.55 | -10.59 | -6.3 | |
| P/B Ratio | 1.38 | 1.58 | 1.44 | 1.39 | 0.8 | |
| PTB ratio | 1.38 | 1.58 | 1.44 | 1.39 | 0.8 | |
| EV to sales | 13.04 | 14.32 | 14.72 | 22.9 | 10.85 | |
| Enterprise value over EBITDA | -11.83 | -9.27 | -7.07 | -5.18 | -3.07 | |
| EV to operating cash flow | -11.18 | -21.27 | -9.4 | -9.32 | -5.34 | |
| EV to free cash flow | -11.1 | -20.94 | -9.26 | -9.03 | -5.28 | |
| Earnings yield | -0.11 | 0.11 | -0.15 | 0.18 | -0.26 | |
| Free cash flow yield | -0.07 | -0.04 | -0.09 | -0.09 | -0.16 | |
| Debt to equity | 0.35 | 0.37 | 0.38 | 0.44 | 0.49 | |
| Debt to assets | 0.24 | 0.24 | 0.26 | 0.28 | 0.3 | |
| Net debt to EBITDA | 2.84 | 1.14 | 1.76 | 0.9 | 0.59 | |
| Current ratio | 3.39 | 3.15 | 8.14 | 6.93 | 3.77 | |
| Interest coverage | -9.93 | -11.57 | -876.25 | -675.91 | -25.29 | |
| Income quality | 0.63 | 0.37 | 0.58 | 0.55 | 0.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.45 | 0.58 | 0.72 | 1.17 | 1.53 | |
| Research and developement to revenue | 0.7 | 0.73 | 0.85 | 1.61 | 1.16 | |
| Intangibles to total assets | 0.43 | 0.47 | 0.42 | 0.45 | 0.49 | |
| Capex to operating cash flow | 0.01 | 0.02 | 0.02 | 0.03 | 0.01 | |
| Capex to revenue | -0.01 | -0.01 | -0.02 | -0.08 | -0.02 | |
| Capex to depreciation | -0.05 | -0.06 | -0.12 | -0.23 | -0.06 | |
| Stock based compensation to revenue | 0.45 | 0.69 | 0.86 | 1.47 | 1.22 | |
| Graham number | 5.86 | 5.14 | 6.07 | 5.58 | 4.61 | |
| ROIC | -0.08 | 0.12 | -0.4 | -0.17 | -0.16 | |
| Return on tangible assets | -0.19 | 0.22 | -0.24 | 0.29 | -0.24 | |
| Graham Net | 0.76 | 0.53 | 0.78 | 0.45 | 0.14 | |
| Working capital | 46.17M | 37.86M | 57.7M | 48.11M | 34.6M | |
| Tangible asset value | 28.44M | 21.59M | 29.09M | 19.85M | 11.1M | |
| Net current asset value | 26.33M | 19.5M | 27.02M | 17.74M | 8.85M | |
| Invested capital | 0.35 | 0.37 | 0.38 | 0.44 | 0.49 | |
| Average receivables | 6.85M | 6.21M | 6.07M | 6.67M | 4.94M | |
| Average payables | 2.15M | 2.1M | 1.67M | 1.69M | 1.53M | |
| Average inventory | 7.86M | 7.42M | 6.4M | 5.69M | 5.27M | |
| Days sales outstanding | 94.35 | 67.26 | 100.47 | 165.44 | 84.75 | |
| Days payables outstanding | 51.26 | 43.48 | 32.02 | 59.7 | 29.22 | |
| Days of inventory on hand | 175.63 | 158.78 | 130.52 | 169.32 | 130.76 | |
| Receivables turnover | 0.95 | 1.34 | 0.9 | 0.54 | 1.06 | |
| Payables turnover | 1.76 | 2.07 | 2.81 | 1.51 | 3.08 | |
| Inventory turnover | 0.51 | 0.57 | 0.69 | 0.53 | 0.69 | |
| ROE | -0.16 | 0.17 | -0.21 | 0.25 | -0.21 | |
| Capex per share | 0 | 0 | -0.01 | -0.01 | 0 |
DRIO Frequently Asked Questions
What is DarioHealth Corp. stock symbol ?
DarioHealth Corp. is a US stock , located in New york of Ny and trading under the symbol DRIO
What is DarioHealth Corp. stock quote today ?
DarioHealth Corp. stock price is $1.21 today.
Is DarioHealth Corp. stock public?
Yes, DarioHealth Corp. is a publicly traded company.
Company Profile
- Volume Average 137.49K
- Market Capitalization 36.21M
- Employee 276
- CEO Mr. Erez Raphael
- Headquarters New York,NY,US
- IPO Date 2016-03-14
-
Website
https://www.mydario.com 
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
